New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Bhubaneswar: Ahead of President Droupadi Murmu’s four-day Odisha visit from July 6 to 9, the…
Bhubaneswar: With the Odisha government likely to soon notify the appointment of senior IAS officer…
Puri: The Odisha government will take all necessary steps to ensure smooth conduct of Rath…
Bhubaneswar: Three buses got stuck on the waterlogged stretch near Iskcon temple as heavy rain lashed…
Bhubaneswar: Capital Police on Wednesday reached the residence of former BJD Minister Raghunandan Das in…
New Delhi: In his new capacity as the Leader of the Opposition in Lok Sabha,…
Bhubaneswar: The Higher Education Department has released the first cut-off list for admission into undergraduate…
Bhubaneswar: Amid speculation about liquor ban in Odisha, Social Security & Empowerment of Persons with…